课题基金 / 基金详情

Glycan-Lectin Receptor Regulation of Macrophage Maturation and Lung InnateDefenses in the Fetus and Newborn Infant

Glycan-Lectin Receptor Regulation of Macrophage Maturation and Lung InnateDefenses in the Fetus and Newborn Infant
胎儿和新生儿巨噬细胞成熟和肺先天防御的聚糖-凝集素受体调节
批准号:
10360375
负责人:
Victor Nizet
金额:
$34.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-07-17 至 2023-06-30
关键词:
AdultAlveolar MacrophagesAmniotic FluidAreaAspirate substanceAutoantigensBacteriaBindingBirthCarbonCell OntogenyCellsCharacteristicsChildhoodCollaborationsCommunicable DiseasesCompetenceDataDefectDetectionDevelopmentDiseaseElementsEnvironmentEpithelialEquationExposure toFDA approvedFetal LungFetusGeneticGenetic ModelsGlycobiologyGlycoproteinsGranulocyte-Macrophage Colony-Stimulating FactorHemolysinHumanITIMImmuneImmune EvasionImmune ToleranceImmune responseImmune signalingImmune systemImmunityImmunocompetenceImmunoglobulinsImmunosuppressionIn VitroInfantInfectionInfectious AgentInflammationInflammatoryInhalationInjuryKnockout MiceLaboratoriesLectin ReceptorsLeukocytesLightLungLung InflammationMacrophage ActivationMammalian CellMeasuresMicrobeMolecularMolecular MimicryMothersMouse ProteinMusNatural ImmunityNeonatalNeutrophil ActivationNeutrophil InfiltrationNewborn InfantOrganPathogenesisPatternPerinatalPhagocytesPharmaceutical PreparationsPharmacologyPhysiciansPneumoniaPolysaccharidesPredispositionPregnancyPremature InfantPreventionPrincipal InvestigatorProteinsPulmonary InflammationRaceRegulationRegulatory PathwayResearch PersonnelRiskRoleScientistSepsisSialic AcidsSideSignal PathwaySignal TransductionSpecialistStreptococcal InfectionsStreptococcus Group BStreptococcus pneumoniaeSurfaceTestingTimeUrineVirulencealveolar epitheliumarmcapsulechronic infectionearly onsetfetalhost-microbe interactionsimmune activationimmune functionimmunoregulationimprovedin uteroin vivoinnovationinsightleukocyte activationlung developmentlung injurylung maturationmacrophagemature animalmimicrymortalitymutantneonatal immune systemneonatal immunityneonatal miceneonatal pneumonianeonatal sepsisneonatenovelpathogenpathogenic microbepatient populationperinatal periodpneumonia modelpneumonia treatmentpreventreceptorresponsescreeningsialic acid binding Ig-like lectinsialic acid receptorsialoadhesinsugartargeted treatmenttherapeutic evaluationtooltranslational approachtreatment groupuptake

项目摘要

项目成果

Victor Nizet的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Summary The fetal and neonatal immune systems maintain a state of tolerance during pregnancy. However the moment that infants are born, their immature immune system must defend against the sudden onslaught of microbial pathogens present in the environment. Unfortunately for many, the transition from tolerance to protection is slow, providing windows of opportunity for specific infectious organisms. This susceptibility is best illustrated by group B Streptococcus (GBS), which is the most common pathogen in neonates but rarely leads to disease in healthy adults. Neonates are first exposed to GBS around delivery, as GBS frequently colonizes the birth canal. Despite efforts around screening and maternal treatment, GBS continues to be the major cause of neonatal pneumonia and early onset sepsis. To discover the mechanisms of GBS infection and immunity in the immature lung, we developed a novel mouse GBS pneumonia model. Adult mice clear GBS within 24 h, quickly resolve the initial lung inflammation, and universally survive GBS infection. However, neonatal mice fail to efficiently kill GBS, develop persistent lung inflammation and injury, and can die from GBS infection. Macrophages, the first line of defense in adult lungs, are immature in neonates making them vulnerable to inhaled and aspirated bacteria including GBS. Our preliminary studies show that immature neonatal lung macrophages fail to mount a normal immune response against GBS or kill phagocytosed bacteria. GBS avoids detection in the neonatal lung by expressing a capsule coated with sialic acid, mimicking “self” antigens in the host. Neonatal lung macrophages express very low levels of sialoadhesin, which facilitates recognition of sialic acid in the GBS capsule and bacterial killing in adults. However neonatal lung macrophages do express Siglec-E, which suppresses inflammatory signaling upon sialic acid binding. This appears to represent a fetal tolerance mechanism, as the amniotic fluid is rich in the sialic acid modified Tamm-Horsfall Protein (THP). We hypothesize that THP and sialic acid maintain immune tolerance in the fetal lung through interactions with macrophage inhibitory Siglecs. For maturation of lung macrophages, THP-sialic acid-Siglec interactions must give way to the ability to detect and kill pathogens. GBS uses its sialic acid rich capsule to mimic the effects of THP, suppressing immune activation in newborn lungs. This proposal will use novel, state of the art approaches to further investigate the molecular mechanisms regulating both immune tolerance in fetal lungs and neonatal immunity against GBS. By bringing together outstanding expertise in the Principal Investigators’ laboratories, state of the art approaches investigating development of lung immunity and mechanisms of host-microbe interactions will shed important new light on the ongoing battle between immunity and microbes around the time of birth. Collectively the aims in this proposal will identify unique molecular mechanisms that make newborns particularly susceptible to GBS pneumonia and explore new translational approaches for protecting newborns. The results will lead to development of new strategies for preventing and treating disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identifying the Most Effective Adjuvant(s) for Leading Group A Streptococcal Vaccine Antigens in Preclinical Mouse and Nonhuman Primate Models
The impact of ampicillin and breast milk oligosaccharides on the infant microbiome and immune functions
The impact of ampicillin and breast milk oligosaccharides on the infant microbiome and immune functions
The impact of ampicillin and breast milk oligosaccharides on the infant microbiome and immune functions
海外基金